Insider · CIK 0001714828

Marshall Keith W

Reports to the SEC for 2 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001714828

Forms 4 and 5

Insider transactions

37 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2023-06-16	Prometheus Biosciences, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−88K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−52.8K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−93K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−136K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−102K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−86.6K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−34.1K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−12.9K sh	—	—	0
2023-06-02	Prometheus Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+78.2K sh	$3.10	+$242K	87,973
2023-06-02	Prometheus Biosciences, Inc.Stock Options (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−78.2K sh	—	—	52,838
2023-04-05	Prometheus Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	$3.70	+$37K	19,811
2023-04-05	Prometheus Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−10K sh	$108.42	−$1.08M	9,811
2023-04-05	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10K sh	—	—	93,040
2023-03-06	Prometheus Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10K sh	$3.70	+$37K	19,811
2023-03-06	Prometheus Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−10K sh	$122.13	−$1.22M	9,811
2023-03-06	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10K sh	—	—	103,040
2023-02-15	Prometheus Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	$3.70	+$18.5K	14,811
2023-02-15	Prometheus Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−5,000 sh	$119.38	−$597K	9,811
2023-02-15	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,000 sh	—	—	113,040
2023-01-17	Prometheus Biosciences, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	$3.70	+$18.5K	14,811
2023-01-17	Prometheus Biosciences, Inc.S Sale	Chief Financial Officer	SSale	−5,000 sh	$119.00	−$595K	9,811
2023-01-17	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,000 sh	—	—	118,040
2022-12-16	Prometheus Biosciences, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+12.9K sh	—	—	12,920
2022-12-09	Prometheus Biosciences, Inc.A Award	Chief Financial Officer	AAward	+9,811 sh	—	—	9,811
2022-12-09	Prometheus Biosciences, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+34.1K sh	—	—	34,085
2022-05-20	Prometheus Biosciences, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+86.6K sh	—	—	86,582
2021-11-14	Prometheus Biosciences, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+102K sh	—	—	102,155
2020-05-22	Histogen Inc.M Exercise/Conversion	EVP, COO & CFO	MExercise/Conversion	+38.5K sh	—	—	38,500
2020-05-22	Histogen Inc.F Tax Payment	EVP, COO & CFO	FTax Payment	−18.6K sh	$0.56	−$10.4K	19,885
2020-05-22	Histogen Inc.Restricted Stock UnitsM Exercise/Conversion	EVP, COO & CFO	MExercise/Conversion	−38.5K sh	—	—	0
2019-08-01	Histogen Inc.Stock Option (Right to Buy)D Disposition to Issuer	EVP, COO & CFO	DDisposition to Issuer	−525K sh	—	—	0
2019-08-01	Histogen Inc.Stock Option (Right to Buy)D Disposition to Issuer	EVP, COO & CFO	DDisposition to Issuer	−70K sh	—	—	0
2019-08-01	Histogen Inc.Stock Option (Right to Buy)D Disposition to Issuer	EVP, COO & CFO	DDisposition to Issuer	−175K sh	—	—	0
2019-08-01	Histogen Inc.Restricted Stock UnitsA Award	EVP, COO & CFO	AAward	+385K sh	—	—	385,000
2019-02-07	Histogen Inc.Stock Option (Right to Buy)A Award	EVP, COO & CFO	AAward	+175K sh	—	—	175,000
2018-02-04	Histogen Inc.Stock Option (Right to Buy)A Award	EVP, COO & CFO	AAward	+70K sh	—	—	70,000
2017-08-31	Histogen Inc.Stock Option (Right to Buy)A Award	EVP, COO & CFO	AAward	+525K sh	—	—	525,000

Recent filings

Accepted (ET)
Jun 164
Marshall Keith W0000899243-23-015754
SEC(opens sec.gov)
Jun 24
Marshall Keith W0001209191-23-034038
SEC(opens sec.gov)
Apr 74
Marshall Keith W0001209191-23-023869
SEC(opens sec.gov)
Mar 84
Marshall Keith W0001209191-23-017435
SEC(opens sec.gov)
Feb 174
Marshall Keith W0001209191-23-010974
SEC(opens sec.gov)
Jan 194
Marshall Keith W0001209191-23-004138
SEC(opens sec.gov)

Companies

Address

C/O CONATUS PHARMACEUTICALS INC. 16745 WEST BERNARDO DRIVE, SUITE 200

SAN DIEGO, CA, 92127